Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 839-848

  Hansson, Emma K ^a   Wallin, Johan E ^a   Lindman, Henrik ^b   Sandström, Marie ^a,c   Karlsson, Mats O ^a   Friberg, Lena E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Anti cancer drugs; Hematologic toxicity; Inter occasion variability; NONMEM; Pharmacodynamics

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG SENSITIVITY; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INDIVIDUALIZATION; INTERINDIVIDUAL VARIABILITY; INTEROCCASION VARIABILITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MITOSIS; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL CONCEPTS; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CELL COUNT; CELL ENLARGEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MYELOPOIESIS; NEOPLASMS; NEUTROPHILS; OBSERVATION; PACLITAXEL; TAXOIDS; TOPOTECAN;

EID: 77649185881     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1089-3     Document Type: Article

References (37)

1. M Sawyer MJ Ratain 2001 Body surface area as a determinant of pharmacokinetics and drug dosing Invest New Drugs 19 171 177 10.1023/A:1010639201787 11392451 (Pubitemid 32423722)
2. J Crawford DC Dale GH Lyman 2004 Chemotherapy-induced neutropenia-risks, consequences, and new directions for its management Cancer 100 228 237 10.1002/cncr.11882 14716755 (Pubitemid 38063629)
3. C Mayers T Panzarella IF Tannock 2001 Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 2246 2257 10.1002/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4 11413512 (Pubitemid 32552809)
4. T Saarto C Blomqvist P Rissanen A Auvinen I Elomaa 1997 Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Br J Cancer 75 301 305 9010042
5. DA Cameron C Massie G Kerr RCF Leonard 2003 Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 1837 1842 10.1038/sj.bjc.6601366 14612889 (Pubitemid 37533256)
6. P Poikonen T Saarto J Lundin H Joensuu C Blomqvist 1999 Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 1763 1766 10.1038/sj.bjc.6690594 10468293 (Pubitemid 29389629)
7. J Wallin LE Friberg MO Karlsson 2009 A tool for neutrophil guided dose adaptation in chemotherapy Comp Meth Prog Biomed 93 283 291 10.1016/j.cmpb.2008. 10.011
8. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 4721 10.1200/JCO.2002.02.140 12488418 (Pubitemid 36025290)
9. IF Troconiz MJ Garrido C Segura, et al. 2006 Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Cancer Chemother Pharmacol 57 727 735 10.1007/s00280-005-0112-6 16261364
10. SJ Kathman DH Williams JP Hodge M Dar 2007 A Bayesian population PK-PD model of ispinesib-induced myelosuppression Clin Pharmacol Ther 81 88 94 10.1038/sj.clpt.6100021 17186004 (Pubitemid 46050871)
11. F Leger WJ Loos R Bugat, et al. 2004 Mechanism-based models for topotecan-induced neutropenia Clin Pharmacol Ther 76 567 578 10.1016/j.clpt.2004.08.008 15592328 (Pubitemid 39601546)
12. EGC Brain K Rezai F Lokiec M Gutierrez S Urien 2008 Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study Br J Clin Pharmacol 65 607 610 10.1111/j.1365-2125.2007.03095.x 18294323
13. JE Latz JJ Rusthoven MO Karlsson A Ghosh RD Johnson 2006 Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Cancer Chemother Pharmacol 57 427 435 10.1007/s00280-005-0035-2 16322992 (Pubitemid 43087585)
14. M Sandstrom H Lindman P Nygren M Johansson J Bergh MO Karlsson 2006 Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients Cancer Chemother Pharmacol 58 143 156 10.1007/s00280-005-0140-2 16465545
15. M Sandstrom H Lindman P Nygren E Lidbrink J Bergh MO Karlsson 2005 Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients J Clin Oncol 23 413 421 10.1200/JCO.2005.09.161 15585753 Jan 20 (Pubitemid 46224216)
16. M Joerger ADR Huitema DJ Richel, et al. 2007 Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin Cancer Res 13 6410 6418 10.1158/1078-0432.CCR-07-0064 17975154 (Pubitemid 350075031)
17. J O'Shaughnessy D Miles S Vukelja, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
18. A Henningsson A Sparreboom M Sandstrom, et al. 2003 Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients Eur J Cancer 39 1105 1114 10.1016/S0959-8049(03) 00126-6 12736110 (Pubitemid 36555868)
19. LJC Vanwarmerdam WWB Huinink S Rodenhuis, et al. 1995 Phase-I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous-infusion J Clin Oncol 13 1768 1776 Jul
20. MJ Ratain R Mick RL Schilsky NJ Vogelzang F Berezin 1991 Pharmacologically based dosing of etoposide-a means of safely increasing dose intensity J Clin Oncol 9 1480 1486 2072147
21. MJ Ratain RL Schilsky KE Choi, et al. 1989 Adaptive-control of etoposide administration-impact of interpatient pharmacodynamic variability Clin Pharmacol Ther 45 226 233 2920497
22. Beal S, Sheiner L (2006) NONMEM users guides. NONMEM Project Group, University of California at San Francisco ed, San Francisco
23. EN Jonsson MO Karlsson 1999 Xpose: an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 51 64 10.1016/S0169-2607(98)00067-4 10195646 (Pubitemid 29049052)
24. R Bruno N Vivier JC Vergniol SL DePhillips G Montay LB Sheiner 1996 A population pharmacokinetic model for docetaxel (Taxotere(R)): model building and validation J Pharmacokinet Biopharm 24 153 172 10.1007/BF02353487 8875345
25. F Leger WJ Loos J Fourcade, et al. 2004 Factors affecting pharmacokinetic variability of oral topotecan: a population analysis Br J Cancer 90 343 347 10.1038/sj.bjc.6601469 14735174 (Pubitemid 38250626)
26. G Toffoli G Corona R Sorio, et al. 2001 Population pharmacokinetics and pharmacodynamics of oral etoposide Br J Clin Pharmacol 52 511 519 10.1046/j.0306-5251.2001.01468.x 11736859
27. GE Cartwright JW Athens MM Wintrobe 1964 The kinetics of granulopoiesis in normal man Blood 24 780 803 14235362
28. MO Karlsson RE Port MJ Ratain LB Sheiner 1994 A population-model for the leukopenic effect of etoposide Clin Pharmacol Ther 55 152 152
29. LE Friberg CJ Brindley MO Karlsson AJ Devlin 2000 Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (DMDC) Eur J Clin Pharmacol 56 567 574 10.1007/s002280000181 11151746
30. PO Gisleskog MO Karlsson SL Beal 2002 Use of prior information to stabilize a population data analysis J Pharmacokinet Pharmacodyn 29 473 505 10.1023/A:1022972420004 12795242
31. MO Karlsson LB Sheiner 1993 The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 21 735 750 10.1007/BF01113502 8138894
32. Gibiansky L (2007) Precision of parameter estimates: covariance step (COV) versus bootstrap procedure (Abstr 1106) [wwwpage-meetingorg/?abstract= 1106], p 16
33. Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks (Abstr 1434) [wwwpage-meetingorg/?abstract=1434], p 17
34. C Kloft J Wallin A Henningsson E Chatelut MO Karlsson 2006 Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: Comparison across anticancer drugs Clin Cancer Res 12 5481 5490 10.1158/1078-0432.CCR-06-0815 17000683 (Pubitemid 44497264)
35. RW Jelliffe A Schumitzky D Bayard, et al. 1998 Model-based, goal-oriented, individualised drug therapy-linkage of population modelling new 'multiple model' dosage design, Bayesian feedback and individualised target goals Clin Pharmacokinet 34 57 77 10.2165/00003088-199834010-00003 9474473 (Pubitemid 28041092)
36. ME de Jonge ADR Huitema JHM Schellens S Rodenhuis JH Beijnen 2005 Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation-a review Clin Pharmacokinet 44 147 173 10.2165/00003088-200544020-00002 15656695 (Pubitemid 40188938)
37. YY Hon WE Evans 1998 Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach Clin Chem 44 388 400 9474050